Prolactinomas: Role of VEGF, FGF-2 and CD31

María, Isabel; Millán, Pérez; Cristina, Carolina; Berner, S.; Becú-Villalobos, Damasia

doi:10.1007/978-94-007-7217-5_3

Cited by 3 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Эта группа аденом неоднородна по своему составу и различается по размеру опухолей, темпам их роста, клинической симптоматике. Если небольшие опухоли эндоселлярной локализации могут сопровождаться лишь клинической картиной гиперпролактинемии и чаще выявляются у женщин, то пролактиномы гигантских размеров склонны к быстрому и инфильтративному росту, часто имеют многоузловой характер строения, проникают в желудочки мозга, кавернозные синусы, основную пазуху, носоглотку, вызывают неврологические и зрительные нарушения; описаны в основном у мужчин и для лечения представляют самую сложную группу из всех пролактином [1,2,3]. До момента появления агонистов дофамина хирургическое лечение было основным методом лечения.…”

Section: актуальностьunclassified

“…Было показано, что плотность сосудов значительно выше в макро-в сравнении с микропролактиномами; в инвазивных пролактиномах в сравнении с неинвазивными; а также в ПРЛ-секретирующих карциномах гипофиза. В ранее проведенных исследованиях было показано, что опухоли, леченные агонистами дофамина, имеют более низкую плотность сосудов в сравнении с первично-оперированными пролактиномами без предшествовавшего лечения каберголином [3,19].…”

Section: A B C D E Funclassified

See 1 more Smart Citation

Changes in the morphological structure of giant prolactinoma during treatment with cabergoline

Astafyeva

Шишкина

Кадашев

et al. 2020

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Currently, cabergoline therapy is the main method of treatment with prolactin. The use of the drug in most cases leads to tumor regression, normalization of prolactin levels and restoration of gonadotropic function. The mechanism of its impact on tumor cells in vivo, which is dynamically traced in the same human tumor, is the case of considerable interest. We observed a 30-year-old patient who was operated on twice for a giant prolactinoma before and on treatment by cabergoline. The morphological study after the first surgery (before introducing of cabergoline therapy) revealed a prolactin-positive pituitary tumor with a Ki-67 labeling index of 8% and with strong expression of dopamine type 2 receptors (D2R), CD31 and CD34. After 4 months, during which the patient received cabergoline at a dose starting from 0.5 mg to 1.5 mg per week, a second transsphenoidal surgery was performed with subtotal removal of residual tumor tissue. During the morphological study of the second biopsy sample, the tumor retained a pronounced immunopositivity to prolactin and D2R, with a decrease in the labeling index Ki-67 to 2%, as well as a decrease in the expression of CD31 and CD34. Subsequent cabergoline therapyresulted in persistent normoprolactinemia, restoration of androgen (and reproductive) status, and no tumor recurrence over a 10-year period on cabergoline treatment. Thus, one of the mechanisms of effect of cabergoline that leads to tumor regression is a decrease in the proliferative index and angiogenesis of the tumor.

show abstract

Section: актуальностьunclassified

Section: A B C D E Funclassified

Changes in the morphological structure of giant prolactinoma during treatment with cabergoline

Astafyeva

Шишкина

Кадашев

et al. 2020

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

show abstract

“…The article titled “Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models” [ 1 ] reused wording from a book chapter published the same year by the same author group, “Prolactinomas: Role of VEGF, FGF-2 and CD31” in Tumors of the Central Nervous System [ 2 ], which was not cited. The review brought together the results of the authors' previous experimental work on angiogenesis and pituitary adenomas in the context of the literature.…”

mentioning

confidence: 99%

Corrigendum to “Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models”

Cristina

Luque

Demarchi

et al. 2020

International Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

Decrease of proliferative potential and vascular density of giant prolactinoma in patients treated with cabergoline

et al. 2020

View full text Add to dashboard Cite

Introduction: Currently, cabergoline therapy is the main treatment for prolactinomas. The use of the drug in most cases leads to regression of the tumor, normalization of prolactin (PRL) levels, and restoration of gonadotropic function. The mechanism of its action in tumor cells “in vivo” tracked in dynamics in the same human tumor is of considerable interest. Materials and Methods: A 30-year-old male was admitted to N.N. Burdenko National Medical Research Center of Neurosurgery. An magnetic resonance imaging (MRI) revealed a giant pituitary adenoma. The level of PRL was more than 5000 mU/l (30-360) (serum dilution was not used to determine PRL). Transcranial microsurgical removal of the tumor was performed. He was treated by cabergoline after surgery. Endoscopic transsphenoidal approach was repeated with subtotal removal of the rest of the tumor. Morphological and immunohistochemical studies of the tumor were done. Results: A morphological study revealed PRL-positive tumor with a Ki-67 LI of 8% with a distinctive expression of D2R, CD31, and CD34 markers. Control MRI in 3 months after surgery revealed remnants of a tumor of endoinfrasellar localization, the tumor remainders were found in endoinfrasellar localization. The tumor retained pronounced immunopositivity to PRL and D2R and a decrease in the Ki-67 to 2% and in the expression of CD31 and CD34. Subsequent therapy with cabergoline resulted in persistent normoprolactinemia, restoration of androgenic function, and absence of tumor recurrence during the 10-year follow-up period. Conclusions: Cabergoline is an effective treatment for prolactinoma, which leads to tumor regression. One of its mechanisms is the reduction of the proliferative index and tumor angiogenesis.

show abstract

Prolactinomas: Role of VEGF, FGF-2 and CD31

Cited by 3 publications

References 28 publications

Changes in the morphological structure of giant prolactinoma during treatment with cabergoline

Changes in the morphological structure of giant prolactinoma during treatment with cabergoline

Corrigendum to “Angiogenesis in Pituitary Adenomas: Human Studies and New Mutant Mouse Models”

Decrease of proliferative potential and vascular density of giant prolactinoma in patients treated with cabergoline

Contact Info

Product

Resources

About